CICC has reaffirmed Sino Biopharmaceutical's (01177) earnings forecast and maintained its "Outperform Industry" rating. The stock currently trades at 29.0x and 26.1x projected 2025/2026 price-to-earnings multiples. Citing upward sector valuation trends, the firm elevated the target price by 26.7% to HK$7.6, implying 34.6x and 31.1x forward P/E ratios with 19.3% upside potential.
On July 15, Sino Biopharmaceutical disclosed plans to acquire 95.09% of Lixin Pharmaceutical for US$950.92 million. Having previously held 4.91% equity, this transaction will render Lixin a wholly-owned subsidiary. Key transaction details reveal a net cash consideration of approximately US$500 million, translating to a US$550 million enterprise value for Lixin.
This valuation represents a 30% premium to Lixin's October 2024 Series C1 financing round, where Sino Biopharmaceutical invested RMB142 million for a 4.91% stake alongside strategic rights to CCR8-targeting antibody LM-108 in mainland China. The final consideration will adjust for pre-closing value leakage and milestone payment variances related to LM-299.
Lixin's innovation credentials gained validation through major licensing deals: AstraZeneca secured global rights to ADC candidate LM-305 in May 2023 for US$55 million upfront plus US$545 million milestones, while Merck obtained worldwide rights to bispecific antibody LM-299 in November 2024 for US$888 million upfront and up to US$2.4 billion in additional milestones. Notably, GenScript Biotech's subsidiary Nanjing Probio, entitled to 40% of LM-299's upfront payment, reported receiving US$213.8 million in milestone payments on June 30.
Post-acquisition, Lixin's pipeline promises transformative potential for Sino Biopharmaceutical's oncology portfolio. Key assets include: - Phase I BIC candidate LM-299 in China - Global Phase I FIC prospect LM-305 - Phase II CCR8 antibody LM-108 - Phase III Claudin 18.2 ADC LM-302 in China - Four additional clinical-stage oncology assets spanning SIRP-α, 4-1BB, and CTLA-4 targets
Risks include delayed product launches and heightened medical insurance cost containment measures.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.